Richard Larson, MD, is a Professor of Medicine in the Section of Hematology/Oncology and Director of the Hematologic Malignancies Clinical Research Program at the University of Chicago. Dr. Larson received his undergraduate degree from Dartmouth College and completed a one year fellowship in nucleic acid chemistry at King’s College, University of Cambridge, UK. He received his medical degree from the Stanford University School of Medicine in 1977, and completed postdoctoral training in Internal Medicine, Hematology, and Medical Oncology at the University of Chicago. Dr. Larson was a Fellow of the Leukemia Society of America and was granted a Clinical Oncology Career Development Award from the American Cancer Society. He has been a member of the faculty in the Section of Hematology/Oncology and the Comprehensive Cancer Center at the University of Chicago since 1983. Dr. Larson was Director of the Leukemia Clinical Research Program at the University of Chicago from 1983 to 2000, during which time he established the adult allogeneic bone marrow transplant program at the University of Chicago Medical Center in 1986. He is Board certified in Internal Medicine, Hematology, and Medical Oncology, and has served as a member of the Hematology Subspecialty Board of the American Board of Internal Medicine.
Dr. Larson is a former Councilor on the Executive Committee of the American Society of Hematology (ASH) and served as the Treasurer of ASH from 2011-2014. He was awarded the Henry M. Stratton Medal for Clinical Science by ASH in 2019, and was the co-chair of the Education Program at the 2004 ASH annual meeting. Dr. Larson has been a faculty member at ASH’s Clinical Research Training Institute, and an invited speaker at the Highlights of ASH in North America, Latin America, Asia, and the Mediterranean. He has represented ASH as a member of the National Cancer Policy Forum of the Institute of Medicine (now the National Academy of Medicine), and is a panel member of the ASH Consult a Colleague program.
During 1997-2011, Dr. Larson was the chair of the Leukemia Committee of the Cancer and Leukemia Group B (CALGB), funded by the National Cancer Institute, NIH, to conduct multicenter clinical trials in patients with cancer. He is currently a member of the National Cancer Institute’s Leukemia Steering Committee.
Dr. Larson is also a member of the American Society of Clinical Oncology and an emeritus member of the American Association for Cancer Research. He is a member of the European LeukemiaNet working groups on chronic myeloid leukemia (CML) and acute myeloid leukemia (AML). Dr. Larson has published more than 500 peer-reviewed articles, reviews, and book chapters on clinical and laboratory studies in human leukemias, and in addition, has served on the editorial boards of Blood, the Journal of Clinical Oncology, and Leukemia. He is a Section Editor for Leukemia and one of two Editors-in-Chief for Hematology for UpToDate, the most widely used point-of-care clinical decision resource for physicians.
Dr. Larson continues to maintain an active clinical practice at the University of Chicago Medical Center. He teaches medical students, nurses, medical residents, and trainees in Hematology and Medical Oncology in the Clinic and at the bedside. Dr. Larson is an attending physician on the inpatient Leukemia Service and the Transplant and Cellular Therapy Service. Throughout his career, his research interests have included clinical trials in acute and chronic leukemias and stem-cell transplantation, experimental therapeutics, the determinants of response to therapy in leukemia and myelodysplastic syndromes, and the etiology of therapy-related leukemias.